Hansa Biopharma to host Capital Markets Day on Thursday October 29, 2020 in Copenhagen
Focusing on transformation into a commercial stage biopharmaceutical company and the potential of its unique antibody-cleaving enzyme platform beyond transplantation in areas such as autoimmunity and gene therapy
Lund, Sweden September 17, 2020. Hansa Biopharma (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company will host its 2020 Capital Markets Day (CMD) in Copenhagen on Thursday October 29, from 13:30-17:30 CET (7:30am-11:30am EST).
The CMD event will be focused around Hansa Biopharma’s transformation into a fully integrated and commercial stage biopharmaceutical company and will highlight the potential of the Company’s unique antibody-cleaving enzyme platform beyond transplantation in areas such as autoimmunity and gene therapy.
The event will feature both senior management and external guest speakers. A detailed agenda is expected to be shared to registrants a few weeks ahead of the CMD. The event will be livestreamed and available for all viewers on our web at http://www.hansabiopharma.com.
If you wish to participate in the CMD virtually, kindly sign up using the following link here.
Due to the COVID-19 pandemic, there will be limitations to the number of physical participants at the CMD. In-person invitations will go out separetaly by email to select institutional investors, analysts and media.
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Mobile: +46 (0) 709-298 269
Head of Corporate Communications
Mobile: +46 (0) 768-198 326
About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, gene therapy and cancer. The Company’s lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020. Hansa’s research and development program is advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.